Literature DB >> 25666294

Monocyte/macrophage-specific NADPH oxidase contributes to antimicrobial host defense in X-CGD.

Yuka Okura1, Masafumi Yamada, Futoshi Kuribayashi, Ichiro Kobayashi, Tadashi Ariga.   

Abstract

BACKGROUND: Chronic granulomatous disease (CGD) is a primary immunodeficiency disease that is characterized by susceptibility to bacterial and fungal infections. Various mutations in CYBB encoding the gp91(phox) subunit of the phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase impair the respiratory burst of all types of phagocytic cells and result in X-linked CGD (X-CGD).
PURPOSE: We here sought to evaluate the underlying cause in an attenuated phenotype in an X-CGD patient. The patient is a 31-year-old male who had been diagnosed as having X-CGD based on the absence of nitroblue tetrazolium reduction and the presence of a CYBB mutation at the age of 1 year. He has been in good health after overcoming recurrent bacterial infections in infancy.
METHODS: We investigated genomic DNA analysis of CYBB gene, residual activity of NADPH oxidase, and expression of gp91(phox) in both polymorphonuclear leukocytes (PMNs) and monocytes/macrophages in the present patient.
RESULTS: Although his underlying germline mutation, c.1016C>A (p.P339H) in the CYBB gene, was identified in both PMNs and monocytes, the expression and functional activity of gp91(phox) retained in monocytes/macrophages, in stark contrast to markedly reduced PMNs.
CONCLUSIONS: Our results indicate that residual reactive oxygen intermediates (ROI) production in PMNs plays an important role in infantile stage in X-CGD, but thereafter retained function of monocytes/macrophages might compensate for the function of NADPH oxidase deficient PMNs and might be an important parameter for predicting the prognosis of X-CGD patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25666294     DOI: 10.1007/s10875-015-0138-4

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  33 in total

1.  Processing and maturation of flavocytochrome b558 include incorporation of heme as a prerequisite for heterodimer assembly.

Authors:  F R DeLeo; J B Burritt; L Yu; A J Jesaitis; M C Dinauer; W M Nauseef
Journal:  J Biol Chem       Date:  2000-05-05       Impact factor: 5.157

2.  Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease.

Authors:  Jacinta Bustamante; Andres A Arias; Guillaume Vogt; Capucine Picard; Lizbeth Blancas Galicia; Carolina Prando; Audrey V Grant; Christophe C Marchal; Marjorie Hubeau; Ariane Chapgier; Ludovic de Beaucoudrey; Anne Puel; Jacqueline Feinberg; Ethan Valinetz; Lucile Jannière; Céline Besse; Anne Boland; Jean-Marie Brisseau; Stéphane Blanche; Olivier Lortholary; Claire Fieschi; Jean-François Emile; Stéphanie Boisson-Dupuis; Saleh Al-Muhsen; Bruce Woda; Peter E Newburger; Antonio Condino-Neto; Mary C Dinauer; Laurent Abel; Jean-Laurent Casanova
Journal:  Nat Immunol       Date:  2011-01-30       Impact factor: 25.606

3.  Development of novel fluorescence probes that can reliably detect reactive oxygen species and distinguish specific species.

Authors:  Ken-ichi Setsukinai; Yasuteru Urano; Katsuko Kakinuma; Hideyuki J Majima; Tetsuo Nagano
Journal:  J Biol Chem       Date:  2002-11-04       Impact factor: 5.157

4.  Abnormal apoptosis in chronic granulomatous disease and autoantibody production characteristic of lupus.

Authors:  A N Sanford; A R Suriano; D Herche; K Dietzmann; K E Sullivan
Journal:  Rheumatology (Oxford)       Date:  2005-10-25       Impact factor: 7.580

5.  Reactive oxygen species produced by the NADPH oxidase 2 complex in monocytes protect mice from bacterial infections.

Authors:  Angela Pizzolla; Malin Hultqvist; Bo Nilson; Melissa J Grimm; Tove Eneljung; Ing-Marie Jonsson; Margareta Verdrengh; Tiina Kelkka; Inger Gjertsson; Brahm H Segal; Rikard Holmdahl
Journal:  J Immunol       Date:  2012-04-09       Impact factor: 5.422

6.  Chronic granulomatous disease in Israel: clinical, functional and molecular studies of 38 patients.

Authors:  Baruch Wolach; Ronit Gavrieli; Martin de Boer; Giora Gottesman; Josef Ben-Ari; Menachem Rottem; Yechiel Schlesinger; Galia Grisaru-Soen; Amos Etzioni; Dirk Roos
Journal:  Clin Immunol       Date:  2008-08-16       Impact factor: 3.969

7.  Chronic granulomatous disease in adults.

Authors:  J G Liese; V Jendrossek; A Jansson; T Petropoulou; S Kloos; M Gahr; B H Belohradsky
Journal:  Lancet       Date:  1996-01-27       Impact factor: 79.321

8.  Chronic granulomatous disease-haematopoietic stem cell transplantation versus conventional treatment.

Authors:  Anders Åhlin; Jakob Fugeläng; Martin de Boer; Olle Ringden; Anders Fasth; Jacek Winiarski
Journal:  Acta Paediatr       Date:  2013-09-10       Impact factor: 2.299

9.  Detection of gp91-phox precursor protein in B-cell lines from patients with X-linked chronic granulomatous disease as an indicator for mutations impairing cytochrome b558 biosynthesis.

Authors:  C D Porter; F Kuribayashi; M H Parkar; D Roos; C Kinnon
Journal:  Biochem J       Date:  1996-04-15       Impact factor: 3.857

10.  The p47phox mouse knock-out model of chronic granulomatous disease.

Authors:  S H Jackson; J I Gallin; S M Holland
Journal:  J Exp Med       Date:  1995-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.